spacer
spacer

PDBsum entry 5vui

Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Oxidoreductase/oxidoreductase inhibitor PDB id
5vui

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
407 a.a.
Ligands
HEM ×2
H4B ×2
M62 ×2
ACT ×2
Metals
_ZN
Waters ×312
PDB id:
5vui
Name: Oxidoreductase/oxidoreductase inhibitor
Title: Structure of rat neuronal nitric oxide synthase heme domain in complex with 7-(((3-fluorophenyl)amino)methyl)quinolin-2-amine dihydrochloride
Structure: Nitric oxide synthase, brain. Chain: a, b. Fragment: unp residues 297-718. Synonym: neuronal nitric oxide synthase, bnos, constitutive nos, nc- nos, nos type i, neuronal nos, nnos, peptidyl-cysteine s-nitrosylase nos1. Engineered: yes
Source: Rattus norvegicus. Rat. Organism_taxid: 10116. Organ: brain. Gene: nos1, bnos. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008.
Resolution:
2.06Å     R-factor:   0.210     R-free:   0.252
Authors: H.Li,T.L.Poulos
Key ref: A.V.Pensa et al. (2017). Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors. J Med Chem, 60, 7146-7165. PubMed id: 28776992
Date:
19-May-17     Release date:   16-Aug-17    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
P29476  (NOS1_RAT) -  Nitric oxide synthase 1 from Rattus norvegicus
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1429 a.a.
407 a.a.
Key:    PfamA domain  Secondary structure

 Enzyme reactions 
   Enzyme class: E.C.1.14.13.39  - nitric-oxide synthase (NADPH).
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: 2 L-arginine + 3 NADPH + 4 O2 + H+ = 2 L-citrulline + 2 nitric oxide + 3 NADP+ + 4 H2O
2 × L-arginine
+ 3 × NADPH
+ 4 × O2
+ H(+)
= 2 × L-citrulline
+ 2 × nitric oxide
+ 3 × NADP(+)
+ 4 × H2O
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
J Med Chem 60:7146-7165 (2017)
PubMed id: 28776992  
 
 
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors.
A.V.Pensa, M.A.Cinelli, H.Li, G.Chreifi, P.Mukherjee, L.J.Roman, P.Martásek, T.L.Poulos, R.B.Silverman.
 
  ABSTRACT  
 
Neuronal nitric oxide synthase (nNOS) is a target for development of antineurodegenerative agents. Most nNOS inhibitors mimic l-arginine and have poor bioavailability. 2-Aminoquinolines showed promise as bioavailable nNOS inhibitors but suffered from low human nNOS inhibition, low selectivity versus human eNOS, and significant binding to other CNS targets. We aimed to improve human nNOS potency and selectivity and reduce off-target binding by (a) truncating the original scaffold or (b) introducing a hydrophilic group to interrupt the lipophilic, promiscuous pharmacophore and promote interaction with human nNOS-specific His342. We synthesized both truncated and polar 2-aminoquinoline derivatives and assayed them against recombinant NOS enzymes. Although aniline and pyridine derivatives interact with His342, benzonitriles conferred the best rat and human nNOS inhibition. Both introduction of a hydrophobic substituent next to the cyano group and aminoquinoline methylation considerably improved isoform selectivity. Most importantly, these modifications preserved Caco-2 permeability and reduced off-target CNS binding.
 

 

spacer

spacer